Vaccine pharmacovigilance in South Africa: successes and limitations of current approaches

REFERENCES

• Abenova M, Shaltynov A, Jamedinova U. Worldwide Child Routine Vaccination Hesitancy Rate among Parents of Children Aged 0-6 Years: A Systematic Review and Meta-Analysis of Cross-Sectional Studies. Vaccines Basel. 2023;12(1).
   PubMed Web of Science ®Google Scholar
• Su Y, Li Y, Zhang S, Chen X. How can COVID-19 vaccines benefit people? A study based on the theory of the commons. Hum Vaccines Immunother. 2023 Aug;19(2):2225991.
   PubMed Web of Science ®Google Scholar
• Tan ST, Park HJ, Rodríguez-Barraquer I, Rutherford GW, Bibbins-Domingo K, Schechter R, et al. COVID-19 Vaccination and Estimated Public Health Impact in California. JAMA Netw Open. 2022 Apr 22;5(4):e228526.10.1001/jamanetworkopen.2022.8526
   PubMed Web of Science ®Google Scholar
• Privor-Dumm L, Excler JL, Gilbert S, et al. Vaccine access, equity and justice: COVID-19 vaccines and vaccination. BMJ Glob Health. 2023 Jun;8(6):e011881.10.1136/bmjgh-2023-011881
   PubMed Web of Science ®Google Scholar
• Van De Pas R, Widdowson MA, Ravinetto R, N Srinivas P, Ochoa TJ, Fofana TO, et al. COVID-19 vaccine equity: a health systems and policy perspective. Expert Rev Vaccines. 2022 Jan 2;21(1):25–36.
   PubMed Web of Science ®Google Scholar
• Dada D, Djiometio JN, McFadden SM, et al. Strategies That Promote Equity in COVID-19 Vaccine Uptake for Black Communities: a Review. J Urban Health. 2022 Feb;99(1):15–27.10.1007/s11524-021-00594-3
   PubMed Web of Science ®Google Scholar
• Bekker LG, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. The Lancet. 2022 Mar;399(10330):1141–1153.10.1016/S0140-6736(22)00007-1
   PubMed Web of Science ®Google Scholar
• Fornasier G, Francescon S, Leone R. An historical overview over Pharmacovigilance. Int J Clin Pharm. 2018;40(4):744–747. doi: 10.1007/s11096-018-0657-1
   PubMed Web of Science ®Google Scholar
• WHO Programme for International Drug Monitoring [Internet]. Available from: https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/.
   Google Scholar
• Weltgesundheitsorganisation, Collaborating Centre for International Drug Monitoring, editors. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO [u.a.]; 2002. 48 p.
   Google Scholar
• World Health Organization, WHO, UMC [Internet]. [cited 2024 Apr 11]. Available from: https://who-umc.org/vigibase/vigibase-services/
   Google Scholar
• Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491–509. doi: 10.1111/bcp.15193
   PubMed Web of Science ®Google Scholar
• Asturias EJ, Wharton M, Pless R. Contributions and challenges for worldwide vaccine safety: the global advisory committee on vaccine safety at 15 years. Vaccine. 2016;34(29):3342–3349. doi: 10.1016/j.vaccine.2016.05.018
   PubMed Web of Science ®Google Scholar
• World Health Organization, WHO. Global Vaccine Safety Blueprint 2012 [Internet]. Available from: https://www.who.int/publications/i/item/WHOIVB12.07
   Google Scholar
• Blau EF, Balakrishnan MR, Skold H, Santhana Gopala Krishnan RS, Lundquist P, Pal S. Progress in Immunization Safety Monitoring - Worldwide, 2020-2022. MMWR Morb Mortal Wkly Rep. 2023;72(49):1321–6.
   PubMed Web of Science ®Google Scholar
• World Health Organization, WHO. Global vaccine action plan 2011-2020.
   Google Scholar
• World Health Organization, WHO. Global Manual on Surveillance of Adverse Events Following Immunization [Internet]. Geneva;[cited 2024 Apr 11]. Available from: https://www.who.int/publications/i/item/9789241507769
   Google Scholar
• World Health Organisation Technical Report Series. Causality Assessment of an adverse event following immunization [Internet]. 2019 [cited 2023 Dec 13]. Available from: iris.who.int
   Google Scholar
• African Union Development Agency NEPAD. An African Perspective on Implementing and Conducting Safety Surveillance of COVID-19 Vaccines 2021 [Internet]. 2024. Available from: https://www.nepad.org/publication/african-perspective-implementing-and-conducting-safety-surveillance-of-covid-19
   Google Scholar
• Ampadu HH, Hoekman J, Bruin ML, Pal SN, Olsson S, Sartori D. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase(R. Drug Saf. 2016;39(4):335–45.
   PubMed Web of Science ®Google Scholar
• Lei J, Balakrishnan MR, Gidudu JF. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015. Vaccine. 2018;36(12):1577–82.
   PubMed Web of Science ®Google Scholar
• Ndagije HB, Walusimbi D, Atuhaire J. Drug safety in Africa: a review of systems and resources for pharmacovigilance. Expert Opin Drug Saf. 2023;22(10):891–895. doi: 10.1080/14740338.2023.2251375
   PubMed Web of Science ®Google Scholar
• World Health Organization, WHO. WHO Global Benchmarking Tool (GBT) for Evaluation of National Regulatory System of Medical Products - Revision VI [Internet]. Geneva: World Health Organization; 2021 [cited 2024 Apr 11]. Available from: https://www.who.int/publications/i/item/9789240020245
   Google Scholar
• World Health Organization WHO. List of National Regulatory Authorities (NRAs) operating at maturity level 3 (ML3) and maturity level 4 ML4 [Internet]. Available from: https://www.who.int/publications/m/item/list-of-nras-operating-at-ml3-and-ml4
   Google Scholar
• Guignard A, Praet N, Jusot V. Introducing new vaccines in low- and middle-income countries: challenges and approaches. Expert Rev Vaccines. 2019;18(2):119–131. doi: 10.1080/14760584.2019.1574224
   PubMed Web of Science ®Google Scholar
• P A, B P, G N. Vaccine safety evaluation: practical aspects in assessing benefits and risks. Vaccine. 2016;34(52):6672–6680. doi: 10.1016/j.vaccine.2016.10.039
   PubMed Web of Science ®Google Scholar
• Black SB, Law B, Chen RT. The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. Vaccine. 2021;39(19):2712–2718. doi: 10.1016/j.vaccine.2021.03.016
   PubMed Web of Science ®Google Scholar
• Stegmann JU, Jusot V, Menang O. Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa. BMC Public Health. 2022;22(1). doi: 10.1186/s12889-022-13867-6
   PubMed Web of Science ®Google Scholar
• Sisay MM, Montesinos-Guevara C, Osman AK, Saraswati PW, Tilahun B, Ayele TA. COVID-19 Vaccine Safety Monitoring Studies in Low- and Middle-Income Countries (LMICs)—A Systematic Review of Study Designs and Methods. LMICs- Syst Rev Study Des Methods Vaccines Basel. 2023;11(6):1035. doi: 10.3390/vaccines11061035
   PubMed Web of Science ®Google Scholar
• World Health Organization WHO. Covid-19 vaccines: safety surveillance manual [Internet]. 2020. Available from: https://www.who.int/publications/i/item/9789240032781
   Google Scholar
• World Health Organization WHO. Protocol template to be used as template for observational study protocols for cohort event monitoring (CEM) for safety signal detection after vaccination with COVID-19 vaccines [Internet]. Geneva: World Health Organization; 2021. Available from: https://www.who.int/publications/i/item/9789240027398
   Google Scholar
• Takuva S, Takalani A, Garrett N, et al. Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study. N Engl J Med. 2021 Aug 5;385(6):570–571.10.1056/NEJMc2107920
   PubMed Web of Science ®Google Scholar
• Peter J, Day C, Takuva S, Takalani A, Engelbrecht I, Garrett N, et al. Allergic reactions to the Ad26.COV2.S vaccine in South Africa. J Allergy Clin Immunol Glob. 2022 Feb;1(1):2–8.
   PubMedGoogle Scholar
• Jacobson BF, Schapkaitz E, Takalani A, Rowji P, Louw VJ, Opie J, et al. Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study). BMJ Med. 2023 Mar;2(1):e000302.
   PubMedGoogle Scholar
• Takalani A, Robinson M, Jonas P, et al. Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa. Vaccine. 2024 Feb;42(6):1195–1199.10.1016/j.vaccine.2024.01.066
   PubMed Web of Science ®Google Scholar
• Jassat W, Abdool Karim S, Mudara C, Welch R, Ozougwu L, Groome M. Clinical severity of COVID-19 patients admitted to hospitals during the Omicron wave in South Africa. medRxiv; 2022.
   Google Scholar
• Law B. SO2-D2. 1.2 Priority List of COVID-19 Adverse events of special interest: Quarterly update December 2020. SPEAC. 2020;
   Google Scholar
• Gray G, Collie S, Goga A, et al. Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against omicron variant in South Africa. N Engl J Med. 2022;386(23):2243–2245. doi: 10.1056/NEJMc2202061
   PubMed Web of Science ®Google Scholar
• Perez-Vilar S, Weibel D, Sturkenboom M, et al. Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine. 2018 Jan;36(3):347–354.10.1016/j.vaccine.2017.05.012
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Moro PL, Chen RT Hospital-based collaboration for epidemiological investigation of vaccine safety: A potential solution for low and middle-income countries? Vaccine. 2018 Jan;36(3):345–346.10.1016/j.vaccine.2017.10.003
   PubMed Web of Science ®Google Scholar
• Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013 Sep;31(40):4448–4458.10.1016/j.vaccine.2013.06.032
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Zuber P, Bonhoeffer J, et al. Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines. Vaccine. 2013 Aug;31(35):3623–3627.10.1016/j.vaccine.2013.05.027
   PubMed Web of Science ®Google Scholar
• NV MJC, MB A, HM G, N B, M, M, T A, et al. ISoP Annu Meet “Putting Patients First Pharmacovigil Int Perspect Glob South” 6–9 Novemb Bali Indones Drug Saf. 2023;22nd(11):1173–295.
   Google Scholar
• World Health Organization, WHO. In: Report of the Meeting of the WHO Global Advisory Committee on Vaccine Safety (GACVS [Internet]. Available from: https://www.who.int/publications/i/item/who-wer9603-13-20
   Google Scholar
• Hagos AA, Sahile Z, Ahmed W. Phanouvong S. Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance. Glob Health Sci Pr. 2024;12(Suppl 1).
   Google Scholar
• Meyer J, Schonfeldt M, Bamford L, Dawood H, Dlamini S, Gray C. COVID-19 Vaccine Safety Surveillance and Causality Assessment of Adverse Events Following Immunisation: Lessons from South Africa. Drug Saf. 2022;45(10):1171–2.
   Web of Science ®Google Scholar
• S.P.E.A.C. The safety platform for emergency vaccines [Internet]. Available from: https://speacsafety.net/
   Google Scholar
• Clinical Data as the Basic Staple of Health Learning: Creating and Protecting a Public Good: Workshop Summary [Internet]. Washington, D.C: National Academies Press; 2010 [cited 2024 Jul 9]. Available from: http://www.nap.edu/catalog/12212
   Google Scholar
• Abouelmehdi K, Beni-Hessane A, Khaloufi H. Big healthcare data: preserving security and privacy. J Big Data. 2018 Dec;5(1):1.10.1186/s40537-017-0110-7
   Google Scholar
• Lu Z Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives. Drug Healthc Patient Saf. 2009 Oct; 35. 35 10.2147/DHPS.S7180
   PubMedGoogle Scholar
• Global Health Network. Global Pharmacovigilance [Internet]. [cited 2024 Jul 2]. Available from: https://globalpharmacovigilance.tghn.org/training/e-learning/
   Google Scholar
• International Soiety of Pharmacovigilance, World Health Organisation Technical Report Series. The WHO-ISoP Pharmacovigilance Curriculum [Internet]. [cited 2024 Jul 8]. Available from: https://link.springer.com/search?query=teaching+pharmacovigilance
   Google Scholar